» Articles » PMID: 31146002

Protective Effect of Shaoyao Decoction Against Colorectal Cancer Via the Keap1-Nrf2-ARE Signaling Pathway

Overview
Date 2019 May 31
PMID 31146002
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Ethnopharmacological Relevance: Ulcerative colitis is one of the three high risk factors for colorectal cancer. Studies have found that about 20% of cancers are caused by repeated chronic inflammatory stimuli over a long period of time. Ulcer-related colorectal cancer is one of the main causes of death in patients with ulcerative colitis. At present, surgery is the first choice for the treatment of colorectal cancer, combined with radiotherapy and chemotherapy, which have serious side effects. However, reportedly, a compound prescription of Chinese traditional medicine Shaoyao Decoction (SYD) commonly used to treat damp-heat dysentery has anti-colorectal cancer effect. Thus this study described the effect of SYD to AOM/DSS-induced colon cancer model.

Aim Of The Study: In this study, modern biomedical approaches were employed for investigating the protective/preventive effects of SYD in mice with azoxymethane (AOM)/DSS-induced CRC.

Materials And Methods: The mice pretreated with AOM/DSS were randomly allocated to SYDL, SYDM, SYDH group and SASP (sulfasalazine) group. Mice without AOM/DSS treatment were randomly divided into PBS control group and SYD control group.

Results: It was found that SYD inhibited the production of inflammatory cytokines, TNF-α, IL-1β, superoxide dismutase (SOD), and malonaldehyde (MDA), and increased the antioxidant indices, as measured by the mRNA expression of GR, TR, HO-1, γ-GCSc, γ-GCSm, NQO-1, UGT1A1, and UGT1A10 in AOM-treated mice. Particularly, the expressions rates of NF-κB and Ki-67 in the SYD-treated experimental groups were significantly lower than those in the model group, indicating that the proliferative ability of the CRC tissues was weaker in the SYD-treated experimental groups. Moreover, the positive levels of Nrf2 in the SYD-treated experimental groups were slightly higher than those in the model group, suggesting that SYD exhibited antioxidant activity.

Conclusions: To sum up, our results suggest that SYD inhibits the development of acute/chronic colitis and prevents colitis-associated CRC by suppressing inflammation and preventing oxidative stress-induced cellular damage.

Citing Articles

The Dual Role of NRF2 in Colorectal Cancer: Targeting NRF2 as a Potential Therapeutic Approach.

Hu M, Yuan L, Zhu J J Inflamm Res. 2024; 17:5985-6004.

PMID: 39247839 PMC: 11380863. DOI: 10.2147/JIR.S479794.


Advances in research on the effectiveness and mechanism of Traditional Chinese Medicine formulas for colitis-associated colorectal cancer.

Wei X, Leng X, Li G, Wang R, Chi L, Sun D Front Pharmacol. 2023; 14:1120672.

PMID: 36909166 PMC: 9995472. DOI: 10.3389/fphar.2023.1120672.


Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study.

Ali F, Ibrahim I, Ghogar O, Abd-Alhameed E, Althagafy H, Hassanein E World J Gastroenterol. 2023; 29(6):1026-1053.

PMID: 36844140 PMC: 9950862. DOI: 10.3748/wjg.v29.i6.1026.


Suppression of microRNA-222-3p ameliorates ulcerative colitis and colitis-associated colorectal cancer to protect against oxidative stress targeting BRG1 to activate Nrf2/HO-1 signaling pathway.

Wang X, Zhang D, Yang Y, Li X, Li H, Zhang X Front Immunol. 2023; 14:1089809.

PMID: 36776858 PMC: 9911687. DOI: 10.3389/fimmu.2023.1089809.


Metabolomics Study of Shaoyao Plants Decoction on the Proximal and Distal Colon in Mice with Dextran Sulfate Sodium-Induced Colitis by UPLC-Q-TOF-MS.

Luo Y, Wu J, Liu Y, Shen Y, Zhu F, Wu J Drug Des Devel Ther. 2022; 16:4343-4364.

PMID: 36583115 PMC: 9792814. DOI: 10.2147/DDDT.S384607.